NIAID Banner Logo Image

HIV Drugs in Development


Drug ClassSponsor and/or CompanyDrug NameAlt NameDrug StatusNotesAIDS#
Antibody, Broadly NeutralizingNational Institute of Allergy and Infectious Diseases (NIAID)SAR441236A tri-specific broadly neutralizing antibody against HIV-1Phase 1Recruiting 
Antibody, MonoclonalColumbia University10E8.4 MabBispecific AntibodyPhase 1Recruiting 
Antibody, MonoclonalRockefeller University3BNC117 -LSHighly neutralizing monoclonal antibody against HIV-1Phase 1Active, Not Recruiting 
Antibody, MonoclonalAbbVieABBV-181BudigalimabPhase 1Recruiting 
Antibody, MonoclonalNational Institute of Allergy and Infectious Diseases (NIAID)CemiplimabAnti-PD-1 AntibodyPhase 1/2Completed 
Antibody, MonoclonalNational Institute of Allergy and Infectious Diseases (NIAID)VRC07-523LSVRC07-523-LS; VRC-HIVMAB075-00-ABPhase 1Active, Not Recruiting 599294
Antibody, MonoclonalNational Institutes of Health Clinical Center (CC)Keytruda™Pembrolizumab, IgG4 kappa monoclonal anti-PD-1 antibodyPhase 1Recruiting 
Antibody, MonoclonalMacroGenics; National Institute of Allergy and Infectious Diseases (NIAID)MGD014JNJ-64052781; HIV-1 x CD3 bispecific DART moleculePhase 1Recruiting 
Antibody, MonoclonalSt George's, University of LondonP2G12Neutralizing monoclonal antibody against HIV-1Phase 1Not Yet Recruiting 578224
Antibody, MonoclonalTaiMed Biologics Inc.; WestatTMB-365anti-CD4 recombinant humanized monoclonal antibodyPhase 1Recruiting 
Antibody, MonoclonalUnited BioPharmaUB-421Monoclonal antibody; mab dB4C7Phase 3Not Yet Recruiting 
Antibody, MonoclonalRockefeller University10-1074Highly neutralizing monoclonal antibody against HIV-1Phase 1Completed 542606
Antibody, MonoclonalOttawa Hospital Research InstituteEntyvio™Vedolizumab; A humanized monoclonal antibodyPhase 2Recruiting 
CRM1 InhibitorKaryopharm TherapeuticsVerdinexorKPT335Phase 1Completed 
Capsid InhibitorGilead SciencesLenacapavirGS-6207Phase 1Completed 599611
CombinationSt. Stephen's AIDS TrustTivicay™ & Rezolsta™Dolutegravir & Darunavir & CobicistatPhase 1Completed 
CombinationNational Institute of Allergy and Infectious Diseases (NIAID)PGT121.414.LS & VRC07-523LSTwo monoclonal antibodiesPhase 1Recruiting 
CombinationNational Institute of Allergy and Infectious Diseases (NIAID)PGT121 & PGDM1400 & 10-1074 & VRC07-523LSFour monoclonal antibodiesPhase 1Active, Not Recruiting 
CombinationJanssen Pharmaceuticals, Inc.; ViiV HealthcareCabenuva™Long acting injectable of Rilpivirine & CabotegravirFDA Approved (January 2021)  
CombinationRockefeller University10-1074-LS-J & 3BNC117-LS-JTwo Broadly Neutralizing Monoclonal AntibodiesPhase 1/2Recruiting 
Entry and/or Fusion InhibitorIncyte CorporationINCB-009471INCB-9471Phase 2Completed 503495
Entry and/or Fusion InhibitorNavigen, Inc.; Covance; National Institute of Allergy and Infectious Diseases (NIAID)CPT31Cholesterol-PIE12-trimerPhase 1Enrolling by invitation 
Entry and/or Fusion InhibitorTobira TherapeuticsCenicrivirocTBR-652; TAK-652Phase 2Completed 224423
Entry and/or Fusion InhibitorFrontier Biotechnologies Co., LtdAlbuvirtideABT; FB006M; Aikening™Phase 3Unknown 531982
Entry and/or Fusion InhibitorRapid PharmaceuticalsAdaptavirRAP101; monomeric d-Ala-peptide T-amide (mDAPTA)Phase 2Unknown 052004
Entry and/or Fusion InhibitorViiV HealthcareCombinectinGSK3732394; BMS-986197Phase 1Completed 594670
Entry and/or Fusion InhibitorCytoDyn, Inc.LeronlimabPRO-140; PA14Phase 2/3Recruiting 088103
Entry and/or Fusion InhibitorViiV Healthcare; GlaxoSmithKlineTemsavirBMS-626529Phase 2Completed 345401
Entry and/or Fusion InhibitorSangamo BioSciencesSB-728-T Phase 1/2Recruiting 
Entry and/or Fusion InhibitorSangamo BioSciencesSB-728-HSCSB-728mR-HSPCPhase 1Active, Not Recruiting 
Entry and/or Fusion InhibitorViiV HealthcareRukobia™Fostemsavir; GSK3684934; BMS-663068; prodrug of BMS-626529FDA Approved July 2020  607788
Entry and/or Fusion InhibitorPfizerPF-00232798 Phase 2Completed 582838
Entry and/or Fusion InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); GenzymeMavorixaforAMD-070; AMD-11070; X4P-001Phase 1/2Completed 495149
HIV Latency Reversing AgentImmune System Regulation ABTriptorelin Gonadotropin Releasing Hormone AgonistPhase 2Recruiting 
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorImperial College London; MerckZolinza™Vorinostat; MK-0683, Suberoylanilide Hydroxamic Acid (SAHA), CCRIS 8456Phase 2Active, Not Recruiting 186714
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorAarhus University HospitalIstodax™RomidepsinPhase 2Active, Not Recruiting 565088
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorMassachusetts General Hospital; NovartisFarydak™Panobinostat Phase 1/2Recruiting 580714
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorMcGill University Health Center; Abbott LabsDepakote™Valproic acid, Divalproex sodium, Valproate(VPA)Phase 2Unknown 057177
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorShenzhen Chipscreen Biosciences Co., LtdEpidaza™CS-055, Chidamide, HBI-8000Phase 2/3Unknown 
HIV Latency-Reversing Agent; Toll-Like Receptor 3 (TLR-3) AgonistNational Institute of Allergy and Infectious Diseases (NIAID); Oncovir, Inc.Hiltonol™Poly-ICLCPhase 1/2Completed 187148
ImmunomodulatorFred Hutchinson Cancer Research CenterCellCept™; Myfortic™Mycophenolate Mofetil; MMFPhase 2Completed 059828
ImmunomodulatorGeorgetown University; AmgenEnbrel™Etanercept; p75 TNFR-Fc fusion proteinPhase 1Completed 
ImmunomodulatorUniversity of MinnesotaIL-15Interleukin 15Phase 1Completed 398478
ImmunomodulatorUniversity of AarhusLefitolimodMGN-1703Phase 2Recruiting 
ImmunomodulatorMerckPEG-Intron™; Pegasys™PEG IFN alpha-2aPhase 3Completed 
ImmunomodulatorNational Institute of Allergy and Infectious Diseases (NIAID); Pfizer (Wyeth)Ammonium Trichlorotellurate; OssireneAS-101Phase 1Completed 000042
ImmunomodulatorNational Institute of Allergy and Infectious Diseases (NIAID)Arava™LeflunomidePhase 1Completed 009747
ImmunomodulatorThe Research Council of NorwayArcoxia™EtoricoxibPhase 2Completed 
Integrase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare; GlaxoSmithKlineVocabria™Cabotegravir GSK1265744; S-265744FDA Approved (January 2021)  598037
Integrase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare; GlaxoSmithKlineCabotegravir, Long-acting InjectableGSK1265744; S-265744 Phase 3Recruiting 598037
Integrase InhibitorBoehringer IngelheimBI-224436 Phase 1Completed 566575
Janus Kinase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID)Ruxolitinib Phase 2Completed 564288
Maturation InhibitorViiV HealthcareGSK3739937 Phase 1Recruiting 
Maturation InhibitorViiV HealthcareGSK3640254 Phase 2Completed 
Maturation InhibitorGlaxoSmithKlineGSK2838232 Phase 2Completed 
MicrobicideMyrexis, Inc.; Panacos PharmaceuticalsBevirimatBVM, PA-457, MPC-4326, DSB, YK-FH312Phase 2Completed 028530
MicrobicideStarpharma Pty LtdVivaGel™SPL-7013 gelPhase 1/2Completed 223863
MicrobicideCONRAD; Uniroyal; Crompton Corp; BiosynUC781ThiocarboxanilidePhase 1Completed 029940
MicrobicideCentre for the AIDS Programme of Research in South Africa; Gilead SciencesTenofovir gelGS-1278; PMPA gel, Apropovir, TFVPhase 3Completed 021800
MicrobicideNational Institute of Allergy and Infectious Diseases (NIAID) ; Population CouncilPC-1005MIV-150 & Zinc Acetate & Carrageenan GelPhase 1Completed 543486
MicrobicideGlaxoSmithKlineGSK706769 Phase 1Completed 
MicrobicidePopulation CouncilGriffithsin Gel Phase 1Completed 336134
MicrobicideJohns Hopkins UniversityDuoGelIQP-0528Phase 1Completed 104929
MicrobicideInternational Partnership for Microbicides, Inc.DS003BMS793Phase 1Completed 335384
MicrobicideInternational Partnership for Microbicides, Inc.; Tibotec Pharmaceuticals; Janssen; Johnson & JohnsonDapivirine Vaginal RingTMC-120, GEL-02, R147681, DAPPhase 3Completed 105293
MicrobicideReprotect, Inc.BufferGel™Carbomer 974P, Carbopol 974P, Carbopol polymerPhase 1Completed 180064
NNRTIViriomElpivirineVM-1500, prodrug of elsulfavirinePhase 2/3Completed 
NNRTIViriomElpida™Elsulfavirine; VM-1500A (long acting injection)Phase 1Unknown 
NNRTISt. Stephen's AIDS TrustTMC278-LAA long-acting formulation of Janssen's RilpivirinePhase 2completed 169030
NNRTIKainos Medicine Inc.KM-023 Phase 1Completed 
NRTIMerckMK-8583Prodrug of tenofovirPhase 1Completed 
NRTIGlaxoSmithKline; Pharmasset, Inc.RacivirRCV; (+/-)FTC, 5-FSddC, LDS-022, PSI 5004Phase 2Completed 005245
NRTIGilead SciencesVemlidy™Tenofovir Alafenamide (Prodrug of tenofovir); GS-7340Phase 3Completed 046774
NRTIMerckMK-8504Prodrug of tenofovirPhase 1Completed 
NRTIMerckIslatravirEFdA; MK-8591Phase 2Active, Not Recruiting 343654
NRTIAchillion Pharmaceuticals; Vion PharmaceuticalsElvucitabineACH-126443; beta-L-Fd4CPhase 2Completed 060327
NRTIRFS Pharma; Biochem Pharma; Triangle Pharmaceuticals; Gilead SciencesAmdoxovirDAPDPhase 2Withdrawn 005431
Protease InhibitorConcert PharmaceuticalsC-10276Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Protease InhibitorTibotec PharmaceuticalsTMC-310911 Phase 2Completed 483146
Protease InhibitorConcert PharmaceuticalsC-10299Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Protease InhibitorConcert PharmaceuticalsC-10297Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Proteasome InhibitorMayo ClinicNinlaro™IxazomibPhase 1Active, Not Recruiting 589853
Rev InhibitorAbivax SAABX464 Phase 2Completed 516635
Toll-Like Receptor 7 (TLR-7) AgonistGilead SciencesVesatolimodGS-9620Phase 2Recruiting 574840
UnidentifiedAbbVieABBV-382 Phase 1Not Yet recruiting 
UnidentifiedMerckMK-4250 Phase 1Completed 
UnidentifiedMerckMK-8527 Phase 1Completed 
UnidentifiedMerckMK-8558 Phase 1Completed 
UnidentifiedShanxi Kangbao Biological Product Co., Ltd.; Chinese Academy of Medical Sciences; Institute of Pathogen BiologyLipovirtide Injection Phase 1Not Yet recruiting 

Sources: ClinicalTrials.gov and sponsor websites.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: January 2021